170 related articles for article (PubMed ID: 17597265)
1. Detection of anti-protective antigen salivary IgG antibodies in recipients of the US licensed anthrax vaccine.
Bienek DR; Chang CK; Cohen ME
Vaccine; 2007 Aug; 25(32):5978-84. PubMed ID: 17597265
[TBL] [Abstract][Full Text] [Related]
2. The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine.
Lininger LA; Cullum ME; Lyles MB; Bienek DR
Vaccine; 2007 Feb; 25(9):1619-25. PubMed ID: 17150286
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ
Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051
[TBL] [Abstract][Full Text] [Related]
4. Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax.
Semenova VA; Schmidt DS; Taylor TH; Li H; Steward-Clark E; Soroka SD; Ballard MM; Quinn CP
Vaccine; 2007 Feb; 25(10):1780-8. PubMed ID: 17229495
[TBL] [Abstract][Full Text] [Related]
5. Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG.
Semenova VA; Schiffer J; Steward-Clark E; Soroka S; Schmidt DS; Brawner MM; Lyde F; Thompson R; Brown N; Foster L; Fox S; Patel N; Freeman AE; Quinn CP
J Immunol Methods; 2012 Feb; 376(1-2):97-107. PubMed ID: 22197974
[TBL] [Abstract][Full Text] [Related]
6. Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine.
Gubbins MJ; Schmidt L; Tsang RS; Berry JD; Kabani A; Stewart DI
J Immunoassay Immunochem; 2007; 28(3):213-25. PubMed ID: 17613668
[TBL] [Abstract][Full Text] [Related]
7. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice.
Sloat BR; Cui Z
J Pharm Pharmacol; 2006 Apr; 58(4):439-47. PubMed ID: 16597361
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women.
Zhang Y; Martin SW; Rose CE; Biagini RE; Franzke LH; Smith JP; Sammons DL; Robertson SA; McNeil MM
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1060-7. PubMed ID: 18781705
[TBL] [Abstract][Full Text] [Related]
10. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
Doolan DL; Freilich DA; Brice GT; Burgess TH; Berzins MP; Bull RL; Graber NL; Dabbs JL; Shatney LL; Blazes DL; Bebris LM; Malone MF; Eisold JF; Mateczun AJ; Martin GJ
J Infect Dis; 2007 Jan; 195(2):174-84. PubMed ID: 17191162
[TBL] [Abstract][Full Text] [Related]
11. Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.
Parreiras PM; Sirota LA; Wagner LD; Menzies SL; Arciniega JL
Vaccine; 2009 Jul; 27(33):4537-42. PubMed ID: 19501205
[TBL] [Abstract][Full Text] [Related]
12. Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum.
Semenova VA; Steward-Clark E; Stamey KL; Taylor TH; Schmidt DS; Martin SK; Marano N; Quinn CP
Clin Diagn Lab Immunol; 2004 Sep; 11(5):919-23. PubMed ID: 15358653
[TBL] [Abstract][Full Text] [Related]
13. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques.
Klinman DM; Xie H; Little SF; Currie D; Ivins BE
Vaccine; 2004 Jul; 22(21-22):2881-6. PubMed ID: 15246624
[TBL] [Abstract][Full Text] [Related]
14. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax.
Quinn CP; Dull PM; Semenova V; Li H; Crotty S; Taylor TH; Steward-Clark E; Stamey KL; Schmidt DS; Stinson KW; Freeman AE; Elie CM; Martin SK; Greene C; Aubert RD; Glidewell J; Perkins BA; Ahmed R; Stephens DS
J Infect Dis; 2004 Oct; 190(7):1228-36. PubMed ID: 15346332
[TBL] [Abstract][Full Text] [Related]
15. Rapid point-of-care test to detect broad ranges of protective antigen-specific immunoglobulin G concentrations in recipients of the U.S.-licensed anthrax vaccine.
Bienek DR; Biagini RE; Charlton DG; Smith JP; Sammons DL; Robertson SA
Clin Vaccine Immunol; 2008 Apr; 15(4):644-9. PubMed ID: 18321882
[TBL] [Abstract][Full Text] [Related]
16. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen.
Quinn CP; Semenova VA; Elie CM; Romero-Steiner S; Greene C; Li H; Stamey K; Steward-Clark E; Schmidt DS; Mothershed E; Pruckler J; Schwartz S; Benson RF; Helsel LO; Holder PF; Johnson SE; Kellum M; Messmer T; Thacker WL; Besser L; Plikaytis BD; Taylor TH; Freeman AE; Wallace KJ; Dull P; Sejvar J; Bruce E; Moreno R; Schuchat A; Lingappa JR; Martin SK; Walls J; Bronsdon M; Carlone GM; Bajani-Ari M; Ashford DA; Stephens DS; Perkins BA
Emerg Infect Dis; 2002 Oct; 8(10):1103-10. PubMed ID: 12396924
[TBL] [Abstract][Full Text] [Related]
17. [Progress on the vaccine for anthrax].
Zhan DW; Wang P; Wang LC; Zhang ZS
Wei Sheng Wu Xue Bao; 2005 Feb; 45(1):149-52. PubMed ID: 15847185
[TBL] [Abstract][Full Text] [Related]
18. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals.
Hewetson JF; Little SF; Ivins BE; Johnson WM; Pittman PR; Brown JE; Norris SL; Nielsen CJ
Vaccine; 2008 Aug; 26(33):4262-6. PubMed ID: 18586363
[TBL] [Abstract][Full Text] [Related]
19. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK
Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249
[TBL] [Abstract][Full Text] [Related]
20. Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine.
Hepburn MJ; Hugh Dyson E; Simpson AJ; Brenneman KE; Bailey N; Wilkinson L; Hornby R; Mateczun AJ; Bell MG; Baillie LW
Vaccine; 2007 Aug; 25(32):6089-97. PubMed ID: 17604880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
